Aerovate Therapeutics unveils IPO

Aerovate Therapeutics, a biopharmaceutical company, has raised $121.5 million for its IPO after pricing its over 8.6 million shares at $14 per share.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this